Helicid (Omeprazole Sodium)

Helicid is an intravenous solution that contains omeprazole sodium, a proton‑pump inhibitor marketed in the European Union. It is supplied in a standard concentration for hospital administration and is prescribed by healthcare professionals for the treatment and prevention of acid‑related gastrointestinal conditions. As a prescription‑only product, Helicid is used under medical supervision to reduce gastric acid secretion through irreversible inhibition of the gastric proton pump.

Helicid is indicated for several acid‑related disorders where reduction of gastric acidity is required.

- Treatment of gastric ulcer - Treatment of duodenal ulcer - Management of gastro‑oesophageal reflux disease (GERD) - Prophylaxis of NSAID‑induced ulceration - Treatment of Zollinger‑Ellison syndrome

The safety profile of Helicid reflects the typical effects observed with intravenous proton‑pump inhibitors.

Common: - Headache - Diarrhea - Nausea - Abdominal pain

Serious: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Elevated liver enzymes

When prescribing Helicid, clinicians should consider several precautionary measures to ensure safe use.

- Assess liver function before initiating therapy. - Use with caution in patients with known hypersensitivity to omeprazole or other PPIs. - Monitor for signs of infection, especially Clostridioides difficile, during prolonged treatment. - Adjust therapy in patients with severe renal impairment if the formulation contains excipients cleared renally. - Evaluate the need for long‑term use, as chronic suppression of gastric acid may affect nutrient absorption. - Consider pregnancy risk; safety data are limited.

Helicid may interact with other medicines, influencing their effectiveness or safety.

Avoid: - Co‑administration with drugs that require an acidic gastric pH for absorption (e.g., ketoconazole, itraconazole, atazanavir). - Concurrent use with rilpivirine‑containing antiretroviral regimens.

Use with caution: - Clopidogrel – reduced antiplatelet effect. - Warfarin – potential alteration of INR. - Methotrexate – increased serum levels. - Digoxin – possible increased concentration.